PP
DYN icon

PDT Partners’s Dyne Therapeutics DYN Stock Holding History

PDT Partners’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-182,986
Closed -$3.32M – 536
2026
Q1 		$3.32M Hold
182,986
– – 0.2% 170
2025
Q4 		$3.58M Sell
182,986
-18,254
-9% -$346K 0.23% 161
2025
Q3 		$2.55M Sell
201,240
-184,008
-48% -$2.1M 0.16% 219
2025
Q2 		$3.67M Buy
385,248
+161,072
+72% +$1.77M 0.21% 169
2025
Q1 		$2.34M Buy
+224,176
New +$3.21M 0.17% 211
2022
Q4 		– Sell
-19,705
Closed -$250K – 705
2022
Q3 		$250K Sell
19,705
-2,918
-13% -$33.5K 0.04% 651
2022
Q2 		$155K Sell
22,623
-4,612
-17% -$31.8K 0.01% 852
2022
Q1 		$263K Sell
27,235
-1,549
-5% -$13.2K 0.02% 749
2021
Q4 		$342K Buy
28,784
+15,275
+113% +$215K 0.03% 639
2021
Q3 		$219K Buy
+13,509
New +$240K 0.02% 670

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

PDT Partners's DYN Position: Q2 2026 in Review

PDT Partners sold out of Dyne Therapeutics (DYN) in Q2 2026, closing a stake of 182,986 shares — an estimated $3.32M sold.

PDT Partners first reported a position in DYN in Q3 2021 and held it in 10 quarters. The position peaked at $3.67M in Q2 2025. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • PDT Partners reported no remaining Dyne Therapeutics position as of Q2 2026 after selling out during the quarter.
  • PDT Partners sold 182,986 Dyne Therapeutics shares in Q2 2026, an estimated $3.32M.
  • PDT Partners first reported a position in Dyne Therapeutics in Q3 2021 and held it in 10 quarters.
  • PDT Partners's Dyne Therapeutics position peaked at $3.67M in Q2 2025.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on PDT Partners's 13F filing for Q2 2026, filed 14 Aug 2026.